Key result
Benzalkonium-heparin-treated Teflon wires linked to higher early fibrinopeptide A levels versus untreated wires.
Why the study?
The thrombogenicity of different angiographic guide wires, including benzalkonium-heparin-treated Teflon-coated, untreated Teflon-coated, and uncoated stainless steel wires, was not well characterized in a model simulating human use.
Does benzalkonium-heparin treatment of Teflon-coated guide wires reduce thrombogenicity compared to untreated Teflon-coated or uncoated stainless steel wires in a canine model?
Does benzalkonium-heparin treatment of Teflon-coated guide wires reduce thrombogenicity compared to untreated Teflon-coated or uncoated stainless steel wires in a canine model?
Benzalkonium-heparin treatment of guide wires does not reduce thrombogenicity within the critical first 10 minutes of insertion, and systemic low-dose heparin effectively eliminates thrombogenicity for all wire types.
No takes yet. Share an insight, caveat, or question.
Benzalkonium-heparin coating conferred no early thrombogenicity advantage in dogs; leaves open whether systemic heparin or alternative coatings reduce guide-wire risk in humans.
Casarella et al. (1977) studied Thrombogenicity of angiographic guide wires. Benzalkonium-heparin-treated Teflon-coated guide wires vs. Untreated Teflon-coated and uncoated stainless steel wires was evaluated on Systemic levels of fibrinopeptide A. Benzalkonium-heparin-treated Teflon-coated guide wires were associated with significantly greater early fibrinopeptide A levels compared to untreated Teflon-coated or stainless steel wires.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: